|

Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

RECRUITINGPhase 2Sponsored by Women's Hospital School Of Medicine Zhejiang University
Actively Recruiting
PhasePhase 2
SponsorWomen's Hospital School Of Medicine Zhejiang University
Started2025-03-10
Est. completion2026-12-31
Eligibility
Age18 Years – 70 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07167160

Summary

Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.

Eligibility

Age: 18 Years – 70 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
2. Positive PD-L1 expression;
3. ECOG score ≤1

Exclusion Criteria:

1. Positive parametrium or surgical margin;
2. Incomplete radical surgery;
3. Residual target lesions;
4. Active autoimmune disease or autoimmune disease requiring systemic treatment;
5. Previous treatment with immune checkpoint inhibitors.

Conditions3

CancerCervical CancerImmunochemotherapy

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.